Fig. 1.

Effect of treatment of a mouse model of type 2 diabetes [high fat (HF) + streptozotocin (STZ)] with menhaden oil or resolvin D1 on glucose utilization. Fasting blood glucose at time 0 for control, diabetic mice, and diabetic mice treated with menhaden oil or resolvin D1 was 111 ± 5, 212 ± 19*, 174 ± 19*, and 180 ± 12* mg/dl, respectively (*P < 0.05, compared with control). Data are the means ± SE. The area under the curve was significantly different (P < 0.01) for untreated and treated diabetic mice vs. control. The number of mice in each group was the same as shown in Table 2.